Human VEGF-R Binding Antibody, Mouse Monoclonal [MA251B-100 or MA251B-025] 

Vascular endothelial growth factor (VEGF) signals through its receptor VEGF-R and plays a critical role during normal embryonic angiogenesis as well as in the pathological angiogenesis that occurs in a number of diseases including age related eye disease, wet AMD (advanced neovascular age-related macular degeneration), and cancer. Soluble VEGF-R-Fc (Eylea), invented by scientists at Regeneron, has been shown to be highly effective as a blocker to inhibit VEGF binding and signaling via VEGF-R. Eylea has been approved to treat age related wet AMD and cancer (References 1-2, see below).

GenHunter has 2 monoclonal antibodies against Eylea (VEGF-R-Fc): a neutralizing mAb (NAb) and a binding mAb with specificity to human VEGF-R (vascular endothelial growth factor receptor).

VEGF-R Antibody & Antigen Products Available:

We also have many other antibody and antigen products (CLICK HERE or names below) including for:
SARS-CoV-2 (COVID-19), Human IL-24, Human IL-20R2, Nplate (Romiplostim), Human VEGF-R, Endo180 (uPARAP, CD280), Tumor Necrosis Factor (TNF) superfamily, SIRPα (Signal-regulatory protein alpha), Rabies virus, Trimer-Tag, RSV (Respiratory Syncytial Virus), HSV-2 (Herpes Simplex Virus 2), and AP (alkaline phosphatase).

References:

1. Holash, J. et al: VEGF-Trap: a VEGF blocker with potent antitumor effects. (2002) PNAS USA. 99:11393-11398. https://www.pnas.org/doi/full/10.1073/pnas.172398299
2. Papadopoulas, N. et al: Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. (2012) Angiogenesis. 15:171-185. https://link.springer.com/article/10.1007/s10456-011-9249-6

All products are FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.